Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sinopharm Group Co ( (HK:1099) ) has issued an update.
Sinopharm Group Co. Ltd. announced its unaudited financial results for the first half of 2025, revealing a slight decrease in total assets by 0.37% and a modest increase in net assets attributable to shareholders by 2.02%. Revenue grew by 3.54% compared to the same period last year, while total profit and net profit attributable to shareholders declined by 6.92% and 5.19% respectively. The company also reported a negative net cash flow from operating activities, indicating potential cash management challenges. These financial indicators suggest a mixed performance, with growth in revenue but a decline in profitability, which may impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a major player in the pharmaceutical industry, primarily engaged in the distribution of pharmaceutical and healthcare products. The company focuses on the Chinese market, with its subsidiary, China National Medicines Corporation Ltd. (SINOPHARM CNCM LTD), listed on the Shanghai Stock Exchange.
Average Trading Volume: 6,129,288
Technical Sentiment Signal: Buy
Current Market Cap: HK$60.38B
For an in-depth examination of 1099 stock, go to TipRanks’ Overview page.